| Developmental Abnormalities |
| Cyl-1-/- |
Cyclin D1 knockout mouse |
| |
| Drug Metabolism & Toxicity |
| GSTP1/2-/- |
Glutathione S-Transferase P1 and P2 double knockout mouse |
| |
| Golgi Apparatus Abnormalities |
| p23+/- |
p23+/- knockout mouse (70% reduction in p23 expressionin tissues) |
| |
| Immune & Lymphatic Abnormalities |
| DR3-/- |
DR3 (Death domain-containing TNFR 3) knockout mouse |
| Pik3ca |
Pi3Kinase C alpha knockin mouse (T208D, K227A), blocking Ras binding |
| SAP-1 |
Saposin-1 knockout mouse |
| |
| Skin Abnormalities |
| Inv-a2b1 |
Human a2 and b1 integrin conditional transgenic mouse (epidermal expression), psoriasis model |
| Inv-a3b1 |
Human a3 and b1 integrin conditional transgenic mouse (epidermal expression), psoriasis model |
| Inv-a5b1 |
Human a5 and b1 integrin conditional transgenic mouse (epidermal expression), psoriasis model |
| InvEE |
Constituitively active MEK1 conditional transgenic mouse (epidermal expression), psoriasis model |
| Inv-IFNg |
Murine interferon-g conditional transgenic mouse (epidermal expression), systemic lupus erythematosus model |
| K5-R2b-null |
Fgfr2 IIIb conditional knockout mouse (epidermal knockout) |
| K14deltaNbeta |
Beta-catenin N-terminal truncation transgenic mouse |
| K14delatNLef1 |
Lef1 N-terminal mutant transgenic mouse |
| K14MycER |
c-Myc protooncogene transgenic mouse |
| |
| Tumour Resistance |
| Pik3ca |
Pi3Kinase C alpha knockin mouse (T208D, K227A), blocking Ras binding |
| |
| Tumourigenesis |
| GSTP1/2-/- |
Glutathione S-Transferase P1 and P2 double knockout mouse |
| Inv-a6b4 |
Human a6 and b4 integrin conditional transgenic mouse (epidermal expression) |
| K5-R2b-null |
Fgfr2 IIIb conditional knockout mouse (epidermal knockout) |
| |
For further information about mouse models from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com
Click here to view disclaimer information. |
